[New Developments in CKD-MBD. Efficacy and safety of antiosteoporotic agents in CKD]

Area of Science:

• Nephrology
• Orthopedics
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) have an elevated risk of fragility fractures.
• Osteoporosis is a significant concern in CKD patients, increasing morbidity and mortality.
• Recent advancements have introduced novel anti-osteoporotic agents, expanding treatment options.

Purpose of the Study:

• To highlight the increased risk of fragility fractures in chronic kidney disease patients.
• To discuss the availability and implications of newly developed anti-osteoporotic agents.
• To emphasize the need for cautious and appropriate use of these agents in CKD.

Main Methods:

• Literature review of recent anti-osteoporotic drug development.
• Analysis of contraindications and safety profiles for CKD patients.
• Clinical considerations for managing bone health in CKD.

Main Results:

• Fragility fractures are a major complication in chronic kidney disease.
• A growing number of anti-osteoporotic medications are now available.
• Some anti-osteoporotic drugs are contraindicated in patients with CKD, necessitating careful prescribing.

Conclusions:

• The management of bone health in CKD requires careful consideration of available anti-osteoporotic therapies.
• Appropriate drug selection is paramount to avoid adverse events and ensure efficacy in CKD patients.
• Further research is needed to guide optimal anti-osteoporotic treatment strategies for individuals with chronic kidney disease.